Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

Celltrion's asthma treatment Omlyclo, a biosimilar of Novartis's Xolair, has received Canadian approval for chronic urticaria, rhinosinusitis, and allergic asthma ...

A new study published in the Ear, Nose and Throat Journal found that the severity of chronic rhinosinusitis with nasal ...

Dr. Sean McWilliams brings two decades of specialized ear, nose and throat expertise to Mid Bay ENT, offering expanded ...

Patients with CRSwNP have a high burden of SCS use and associated health care costs, especially when they have comorbid asthma.

Comorbid asthma, nonsmoking status, and the ethmoid/maxillary sinus ratio were significant predictors of eosinophilic CRSwNP.

Dupilumab was effective for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) at 52 weeks.

The nasal corticosteroids market is experiencing robust growth, fueled by the rising prevalence of chronic respiratory ...

Priyanka Chopra opened up about a cosmetic procedure she deeply regrets. During an interview on Howard Stern’s radio show, ...

Nasal congestion happens when passages in the nasal cavity are blocked. 1 When nasal passages are blocked, nasal breathing can be more challenging, meaning it is harder to breathe through the nose ...

Discover how asthma contributes to bronchiectasis development through sinusitis and inflammation. Learn about new findings ...